Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity

Genes, Brain and Behavior

Volumn 9, Issue 4, 2010, Pages 365-371

  Benedetti, F ^a   Poletti, S ^a,b   Radaelli, D ^a   Bernasconi, A ^a   Cavallaro, R ^a   Falini, A ^a   Lorenzi, C ^a   Pirovano, A ^a   Dallaspezia, S ^a   Locatelli, C ^a   Scotti, G ^a   Smeraldi, E ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Antipsychotic; Brain imaging; Glycogen synthase kinase 3 ; Grey matter; Neuronal resilience; Schizophrenia

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ADULT; ARTICLE; BRAIN SIZE; CHRONIC DISEASE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL LOBE;

ADULT; APOPTOSIS; ATROPHY; CHRONIC DISEASE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; NERVE DEGENERATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 77953009325     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2010.00566.x     Document Type: Article

References (39)

1. Adli, M., Hollinde, D.L., Stamm, T., Wiethoff, K., Tsahuridu, M., Kirchheiner, J., Heinz, A. & Bauer, M. (2007) Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. Biol Psychiatry 62, 1295 1302.
2. Ashburner, J. & Friston, K.J. (2005) Unified segmentation. Neuroimage 26, 839 851.
3. Beaulieu, J.M., Sotnikova, T.D., Yao, W.D., Kockeritz, L., Woodgett, J.R., Gainetdinov, R.R. & Caron, M.G. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101, 5099 5104.
4. Beaulieu, J.M., Zhang, X., Rodriguiz, R.M., Sotnikova, T.D., Cools, M.J., Wetsel, W.C., Gainetdinov, R.R. & Caron, M.G. (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A 105, 1333 1338.
5. Beaulieu, J.M., Gainetdinov, R.R. & Caron, M.G. (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49, 327 347.
6. Benedetti, F., Bernasconi, A., Lorenzi, C., Pontiggia, A., Serretti, A., Colombo, C. & Smeraldi, E. (2004a) A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 355, 37 40. (Pubitemid 38077179)
7. Benedetti, F., Serretti, A., Colombo, C., Lorenzi, C., Tubazio, V. & Smeraldi, E. (2004b) A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 368, 123 126. (Pubitemid 39194855)
8. Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C. & Smeraldi, E. (2005) Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta-50 T/C SNP. Neurosci Lett 376, 51 55.
9. Bozzi, Y. & Borrelli, E. (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci 29, 167 174.
10. Church, S.M., Cotter, D., Bramon, E. & Murray, R.M. (2002) Does schizophrenia result from developmental or degenerative processes? J Neural TransmSuppl 63, 129 147.
11. Dolcos, F., Rice, H.J. & Cabeza, R. (2002) Hemispheric asymmetry and aging: right hemisphere decline or asymmetry reduction. Neurosci Biobehav Rev 26, 819 825.
12. Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M. & Gogos, J.A. (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36, 131 137.
13. Farrow, T.F., Whitford, T.J., Williams, L.M., Gomes, L. & Harris, A.W. (2005) Diagnosis-related regional gray matter loss over two years in first episode schizophrenia and bipolar disorder. Biol Psychiatry 58, 713 723.
14. Fatemi, S.H. & Folsom, T.D. (2009) The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35, 528 548.
15. Forde, J.E. & Dale, T.C. (2007) Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 64, 1930 1944.
16. Glantz, L.A., Gilmore, J.H., Lieberman, J.A. & Jarskog, L.F. (2006) Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 81, 47 63.
17. Good, C.D., Johnsrude, I.S., Ashburner, J., Henson, R.N., Friston, K.J. & Frackowiak, R.S. (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14, 21 36.
18. Gould, T.D. & Manji, H.K. (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223 1237.
19. Gould, T.D., Picchini, A.M., Einat, H. & Manji, H.K. (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 7, 1399 1409.
20. Honea, R., Crow, T.J., Passingham, D. & Mackay, C.E. (2005) Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 162, 2233 2245.
21. Inkster, B., Nichols, T.E., Saemann, P.G., Auer, D.P., Holsboer, F., Muglia, P. & Matthews, P.M. (2009) Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 66, 721 728.
22. Iritani, S. (2007) Neuropathology of schizophrenia: a mini review. Neuropathology 27, 604 608.
23. Kalinderi, K., Fidani, L., Katsarou, Z., Clarimon, J., Bostantjopoulou, S. & Kotsis, A. (2009) GSK3beta polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. NeurobiolAging, in press.
24. Kockeritz, L., Doble, B., Patel, S. & Woodgett, J.R. (2006) Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 7, 1377 1388.
25. Koros, E. & Dorner-Ciossek, C. (2007) The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect 20, 437 445.
26. Kwok, J.B., Hallupp, M., Loy, C.T., Chan, D.K., Woo, J., Mellick, G.D., Buchanan, D.D., Silburn, P.A., Halliday, G.M. & Schofield, P.R. (2005) GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58, 829 839.
27. Lovestone, S., Killick, R., Di Forti, M. & Murray, R. (2007) Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30, 142 149.
28. Manji, H.K., Moore, G.J., Rajkowska, G. & Chen, G. (2000) Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 5, 578 593.
29. Mao, Y., Ge, X., Frank, C.L., Madison, J.M., Koehler, A.N., Doud, M.K., Tassa, C., Berry, E.M., Soda, T., Singh, K.K., Biechele, T., Petryshen, T.L., Moon, R.T., Haggarty, S.J. & Tsai, L.H. (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136, 1017 1031.
30. Mateo, I., Vazquez-Higuera, J.L., Sanchez-Juan, P., Rodriguez-Rodriguez, E., Infante, J., Garcia-Gorostiaga, I., Berciano, J. & Combarros, O. (2009) Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk. Acta Neurol Scand 120, 130 133.
31. McCarley, R.W., Wible, C.G., Frumin, M., Hirayasu, Y., Levitt, J.J., Fischer, I.A. & Shenton, M.E. (1999) MRI anatomy of schizophrenia. Biol Psychiatry 45, 1099 1119.
32. Nair, V.D. & Olanow, C.W. (2008) Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem 283, 15469 15478.
33. Phillips, O.R., Nuechterlein, K.H., Clark, K.A., Hamilton, L.S., Asarnow, R.F., Hageman, N.S., Toga, A.W. & Narr, K.L. (2008) Fiber tractography reveals disruption of temporal lobe white matter tracts in schizophrenia. Schizophr Res 107, 30 38.
34. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R. & Kouassi, E. (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63, 801 808.
35. Sotnikova, T.D., Beaulieu, J.M., Gainetdinov, R.R. & Caron, M.G. (2006) Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets 5, 45 56.
36. Takahashi, T., Wood, S.J., Yung, A.R., Soulsby, B., McGorry, P.D., Suzuki, M., Kawasaki, Y., Phillips, L.J., Velakoulis, D. & Pantelis, C. (2009) Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry 66, 366 376.
37. Tsai, S.J., Liou, Y.J., Hong, C.J., Yu, Y.W. & Chen, T.J. (2008) Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 8, 384 390.
38. Wang, Y., Huang, W., Wang, C., Tsai, C., Chen, C., Chang, Y., Kai, J. & Lin, C. (2009) Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. Br J Pharmacol 157, 1004 1013.
39. Witthaus, H., Brune, M., Kaufmann, C., Bohner, G., Ozgurdal, S., Gudlowski, Y., Heinz, A., Klingebiel, R. & Juckel, G. (2008) White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophr Res 102, 141 149.